pyrazines has been researched along with Hormone-Dependent Neoplasms in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujisawa, M; Miyake, H; Sakai, I; Terakawa, T | 1 |
| Begus-Nahrmann, Y; Beissbarth, T; Eick, D; Gorsler, T; Hennion, M; Hintermair, C; Hsu, C; Johnsen, SA; Kramer, F; Kremmer, E; Prenzel, T; Simons, M | 1 |
| Arteaga, CL; Balko, JM; Buck, E; Fox, EM; González-Angulo, AM; Kuba, MG; Liu, S; Manning, HC; Miller, TW; Mills, GB; Sánchez, V; Shyr, Y; Smith, RA; Ye, F | 1 |
| Adams, J; Daliani, DD; Dieringer, P; Elliott, P; Esseltine, D; Kim, J; Logothetis, CJ; Madden, T; Millikan, RE; Nix, D; Pagliaro, L; Papandreou, CN; Perez, C; Petrusich, A; Pien, CS; Tu, SM; Wang, X; Yang, H | 1 |
| Logothetis, CJ; Papandreou, CN | 1 |
| Agus, D; Dreicer, R; Petrylak, D; Roth, B; Webb, I | 1 |
| Nakayama, M; Nishimura, K; Nonomura, N; Okuyama, A; Takayama, H | 1 |
2 review(s) available for pyrazines and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Bortezomib as a potential treatment for prostate cancer.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Endopeptidases; Humans; Male; Multienzyme Complexes; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2004 |
[Molecular-targeted therapy for prostate cancer].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Male; Neoplasms, Hormone-Dependent; NF-kappa B; Prostatic Neoplasms; Pyrazines; Thalidomide | 2008 |
2 trial(s) available for pyrazines and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multienzyme Complexes; Neoplasms; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Statistics, Nonparametric | 2004 |
Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgens; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Docetaxel; Dose-Response Relationship, Drug; Humans; Interleukin-6; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrazines; Taxoids | 2007 |
3 other study(ies) available for pyrazines and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin-6 in the androgen-independent human prostate cancer PC3 model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Docetaxel; Enzyme-Linked Immunosorbent Assay; Humans; Interleukin-6; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinases; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Pyrazines; RNA, Small Interfering; Taxoids; Tumor Cells, Cultured | 2011 |
Estrogen-dependent gene transcription in human breast cancer cells relies upon proteasome-dependent monoubiquitination of histone H2B.
Topics: Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Estrogens; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histones; Humans; Neoplasms, Hormone-Dependent; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Transcription, Genetic; Ubiquitination | 2011 |
A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Disease-Free Survival; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Insulin; Insulin-Like Growth Factor I; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Protein-Tyrosine Kinases; Pyrazines; Random Allocation; Receptor, IGF Type 1; Receptor, Insulin; Receptors, Estrogen; RNA Interference; Signal Transduction; Tamoxifen; Xenograft Model Antitumor Assays | 2011 |